27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
This is the first study to investigate the effect of MAKSCog, an individualised CCT, specifically developed for people with different subtypes of MCI. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
A total of 103 participants completed all investigations and were included in the analysis. 5 key findings →
Participants: 103 Evidence: low
Full summary, score breakdown and related studies → Original source
We investigated self-rating of cognitive task performance (self-appraisal) and the difference between self-rating and actual task performance (appraisal discrepancy) in cognitively healthy older adults and their relationship with cortical thickness and Alzheimer's disease (AD) biomarkers, amyloid and tau. 4 key findings →
Participants: 151 Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with AD were clustered into 4 subtypes reproducibly, which included those with 1) diffuse and mild functional connectivity disruption (subtype 1), 2) predominantly decreased connectivity in the default mode network accompanied by an increase in the prefrontal circuit (subtype 2), 3) predominantly decreased connectivity in the anterior cingulate cortex accompanied by an increase in prefrontal cortex connectivity (subtype 3), and 4) predominantly decreased connectivity in the basal ganglia accompanied by an increase in prefrontal cortex connectivity (subtype 4). 3 key findings →
Participants: 809 Evidence: low
Full summary, score breakdown and related studies → Original source
Comparison of SUVR in different brain regions demonstrated significant differences in the temporal, occipital and cerebellar cortices. 4 key findings →
Participants: 830 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 157 subjects with a mean age of 71.8 (±7.7) included in this study, 76 individuals were stratified as metformin users. 5 key findings →
Participants: 157 Evidence: low
Full summary, score breakdown and related studies → Original source
Both groups were comparable in age (mean = 74 ± 7.2 years in the placebo group and 75 ± 7.4 in the intervention group) and in other demographics. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Patients treated with bryostatin pre-specified at Mini-Mental State Examination scores 10-14, without memantine, showed baseline balance, complete safety, and SIB improvements at 13 weeks with multiple imputation analysis: Study #203 = 4.1 SIB points above baseline (p = 0.005), and Study #202 = 4.2 SIB points above baseline (p = 0.016). 3 key findings →
Participants: 95 Evidence: low
Full summary, score breakdown and related studies → Original source
aMCI-HCR compared to aMCI-LCR patients showed significant decrease of CTh in the right temporal and in the left prefrontal lobe. 5 key findings →
Participants: 278 Evidence: low
Full summary, score breakdown and related studies → Original source
To assess the validity of Yaakov Stern's theory, which postulates that the first cognitive deficits of Alzheimer disease are delayed in patients with high cognitive reserve, compared to those with low cognitive reserve, but this is subsequently associated with faster cognitive decline when cerebral lesions have reached a certain degree of severity. 3 key findings →
Participants: 318 Evidence: low
Full summary, score breakdown and related studies → Original source
Previous genome-wide association studies have identified numerous genetic variants and revealed the genetic architecture of educational attainment, another marker of cognitive reserve. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Compared with LLD patients without OI impairment and normal controls, LLD patients with OI impairment exhibited increased FC between the left orbital frontal cortex (OFC) and left calcarine gyrus, between the left OFC and right lingual gyrus, between the right OFC and right rectus gyrus, and decreased FC between the right piriform cortex and right superior parietal lobule. 5 key findings →
Participants: 150 Evidence: low
Full summary, score breakdown and related studies → Original source
LOD patients exhibited lower OI scores than EOD patients and normal controls (NCs). 5 key findings →
Participants: 179 Evidence: low
Full summary, score breakdown and related studies → Original source
Age of acquisition of nouns (p = 0.034, |d| = 0.77) and lexical density (p = 0.0064, |d| = 0.72) were reduced in SYN + AD, and together showed excellent discrimination for SYN + AD vs. SYN-AD (95% sensitivity, 66% specificity; AUC = 0.82). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Research on interpersonal interaction dynamics in relationships between persons with dementia and their family caregivers has been limited. 5 key findings →
Participants: 350 Evidence: low
Full summary, score breakdown and related studies → Original source
As hypothesized, residents who exhibited a greater number of positive reactive behaviors while listening to music also evidenced more improvements in their confusion, disengagement, unresponsiveness, and restlessness after their music-listening session. 3 key findings →
Participants: 101 Evidence: low
Full summary, score breakdown and related studies → Original source
Of the study population, 97% had a limited care plan (ACP I) documented. 5 key findings →
Participants: 367 Evidence: low
Full summary, score breakdown and related studies → Original source
There were significant differences in plasma p‐tau181 values between Controls and those with AD at all ages up to 85 years. 5 key findings →
Participants: 1,558 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma p‐tau181 differentiated pathology‐confirmed AD from NC with negative amyloid PET scans with an AUC of 0.93. 5 key findings →
Participants: 91 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In cognitively unimpaired adults, elevated plasma p-tau181 is associated with future increased Aβ deposition across multiple brain regions. 5 key findings →
Participants: 18 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Several recent research studies show high performance of blood biomarkers to identify Alzheimer's disease also in the pre-dementia mild cognitive impairment (MCI) stage, but data from the routine clinical care memory clinic setting are needed. 1 key finding →
Participants: 54 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Participants had a mean age of 71.3 (SD 4.6) years; 40.6% were male; and 34.6% were APOE ε4 positive. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
TSPO and x c - overexpression can be assessed by [ 18 F]DPA-714 and [ 18 F]FSPG, respectively, and correlate with the level of Aβ plaque deposition obtained with a PET amyloid tracer. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The hippocampus has a well-established role in spatial and episodic memory but a broader function has been proposed including aspects of perception and relational processing. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
On clinical data, this innovative approach for early diagnosis might provide more insight into pathophysiological processes underlying degenerative changes, as well as toward a personalized risk evaluation for pharmacological, nonpharmacological, and rehabilitation treatments. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →